A Phase II Study of MT-401 after Stem Cell Transplantation in People with Acute Myeloid Leukemia

Share
Print

Full Title

A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-401) Administered to Patients with Acute Myeloid Leukemia (AML) following Hematopoietic Stem Cell Transplantation

Purpose

The purpose of this study is to determine the best dose of an investigational treatment called MT-401 to be given after a donated (allogeneic) stem cell transplant in patients with acute myeloid leukemia (AML). MT-401 is made from T cells (a type of white blood cell) collected from the donor who provided the stem cells for the bone marrow transplant. These cells are sent to a laboratory and changed to enable them to bind to and kill cancer cells. MT-401 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have AML and be planning to have an allogeneic stem cell transplant or have cancer that persists after already having a stem cell transplant.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Boglarka Gyurkocza at 646-608-3768.

Protocol

21-059

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators